We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?
Read MoreHide Full Article
Medtronic plc’s (MDT - Free Report) Restorative TherapiesGroup (“RTG”) has been on a strong growth trajectory of late, on encouraging contributions from the majority of sub-segments.
We expect this strength to reflect in the fourth quarter and fiscal 2018 results, which are scheduled to release before the opening bell on May 24.
Click here to know how the company’s overall Q4 performance is expected to be.
RTG in Focus
Medtronic’s RTG presently comprises of Spine, Brain Therapies, Specialty Therapies and Pain Therapies divisions. We note that management expects 3-4% revenue growth in RTG business in the fourth quarter of fiscal 2018. Per management, this guidance balances the ongoing strength in Pain and Brain Therapies segments with any adverse impact from the weakening spine market.
Consequently, RTG’s Zacks Consensus Estimate for revenues of $2.09 billion indicates rise of 60.8% from the year-ago quarter.
In the last reported quarter, the segment recorded improvement in sales, driven by low-double-digit growth in Brain Therapies, mid-single-digit growth in Specialty Therapies and high-single-digit growth in Pain Therapies at CER. However, revenues from the Spine business remained flat at CER on a year-over-year basis.
Let's see how things are shaping up in these sub-segments before fourth-quarter results.
Brain Therapies: In Brain Therapies, which now includes Neurovascular and Neurosurgery businesses, the company has been witnessing major developments. In the Neurovascular business, which received solid contributions from stroke portfolio in the last reported quarter, Medtronic announced the receipt of FDA approval for the Riptide Aspiration System in January 2018. This adds a valuable tool to the company’s Acute Ischemic Stroke (AIS) product portfolio benefit of which should get reflected from the yet-to-be-reported quarter itself.
Further, in April, Medtronic announced the CE Mark receipt and launch of the Visualase MRI-Guided Laser Ablation System in Europe. Notably, the Visualase system can be used in neurosurgery procedures and provides advanced MRI-guided laser ablation technology. These developments should help the company continue to witness strength in the Brain Therapies business.
Pain Therapies: The Pain Therapies division, which now includes Pain (Spinal Cord Stimulation and Drug Pumps) and Interventional Spine businesses, contributed encouragingly to the company’s top line in third-quarter fiscal 2018. Pain Therapies witnessed growth on the solid uptake of Intellis platform for spinal-cord stimulation as well as strength in drug pumps.
In January, the company announced the receipt of FDA approval for a new clinician programmer for use with the SynchroMed II Intrathecal Drug Delivery system. Again, in April, Medtronic announced its U.S. launch of OptiSphere embolization spheres, a resorbable embolic platform, developed for embolization of hypervascular tumors.
In view of the company’s efforts to develop its Pain Therapies division,we believe that solid trend will continue to reflect in the to-be-reported quarter results as well.
Spine: Medtronic’s Spine division includes the Core Spine, BMP and Kanghui businesses. In the last reported quarter, a low-single-digit decline in Core Spine was more than offset by mid-single-digit growth in BMP at CER.
Per management, the combination of enabling technologies like imaging, navigation, powered instruments, nerve monitoring and Mazor Robotics with spine implants has spurred growth in this division.
We expect encouraging top-line contributions from the business in the to-be-reported quarter.
Zacks Rank & Stocks to Consider
Medtronic currently carries a Zacks Rank #3 (Hold).
Intuitive Surgical has a long-term expected earnings growth rate of 12.1%.
Illumina has a long-term expected earnings growth rate of 20%.
Amedisys has a long-term expected earnings growth rate of 17.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
Image: Bigstock
Will Strong RTG Arm Drive Medtronic's (MDT) Q4 Earnings?
Medtronic plc’s (MDT - Free Report) Restorative TherapiesGroup (“RTG”) has been on a strong growth trajectory of late, on encouraging contributions from the majority of sub-segments.
We expect this strength to reflect in the fourth quarter and fiscal 2018 results, which are scheduled to release before the opening bell on May 24.
Click here to know how the company’s overall Q4 performance is expected to be.
RTG in Focus
Medtronic’s RTG presently comprises of Spine, Brain Therapies, Specialty Therapies and Pain Therapies divisions. We note that management expects 3-4% revenue growth in RTG business in the fourth quarter of fiscal 2018. Per management, this guidance balances the ongoing strength in Pain and Brain Therapies segments with any adverse impact from the weakening spine market.
Consequently, RTG’s Zacks Consensus Estimate for revenues of $2.09 billion indicates rise of 60.8% from the year-ago quarter.
Medtronic PLC Price and EPS Surprise
Medtronic PLC Price and EPS Surprise | Medtronic PLC Quote
In the last reported quarter, the segment recorded improvement in sales, driven by low-double-digit growth in Brain Therapies, mid-single-digit growth in Specialty Therapies and high-single-digit growth in Pain Therapies at CER. However, revenues from the Spine business remained flat at CER on a year-over-year basis.
Let's see how things are shaping up in these sub-segments before fourth-quarter results.
Brain Therapies: In Brain Therapies, which now includes Neurovascular and Neurosurgery businesses, the company has been witnessing major developments. In the Neurovascular business, which received solid contributions from stroke portfolio in the last reported quarter, Medtronic announced the receipt of FDA approval for the Riptide Aspiration System in January 2018. This adds a valuable tool to the company’s Acute Ischemic Stroke (AIS) product portfolio benefit of which should get reflected from the yet-to-be-reported quarter itself.
Further, in April, Medtronic announced the CE Mark receipt and launch of the Visualase MRI-Guided Laser Ablation System in Europe. Notably, the Visualase system can be used in neurosurgery procedures and provides advanced MRI-guided laser ablation technology. These developments should help the company continue to witness strength in the Brain Therapies business.
Pain Therapies: The Pain Therapies division, which now includes Pain (Spinal Cord Stimulation and Drug Pumps) and Interventional Spine businesses, contributed encouragingly to the company’s top line in third-quarter fiscal 2018. Pain Therapies witnessed growth on the solid uptake of Intellis platform for spinal-cord stimulation as well as strength in drug pumps.
In January, the company announced the receipt of FDA approval for a new clinician programmer for use with the SynchroMed II Intrathecal Drug Delivery system. Again, in April, Medtronic announced its U.S. launch of OptiSphere embolization spheres, a resorbable embolic platform, developed for embolization of hypervascular tumors.
In view of the company’s efforts to develop its Pain Therapies division,we believe that solid trend will continue to reflect in the to-be-reported quarter results as well.
Spine: Medtronic’s Spine division includes the Core Spine, BMP and Kanghui businesses. In the last reported quarter, a low-single-digit decline in Core Spine was more than offset by mid-single-digit growth in BMP at CER.
Per management, the combination of enabling technologies like imaging, navigation, powered instruments, nerve monitoring and Mazor Robotics with spine implants has spurred growth in this division.
We expect encouraging top-line contributions from the business in the to-be-reported quarter.
Zacks Rank & Stocks to Consider
Medtronic currently carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical sector are Intuitive Surgical (ISRG - Free Report) , Illumina, Inc (ILMN - Free Report) and Amedisys, Inc. (AMED - Free Report) . While Intuitive Surgical and Illumina sport a Zacks Rank #1 (Strong Buy), Amedisys carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Intuitive Surgical has a long-term expected earnings growth rate of 12.1%.
Illumina has a long-term expected earnings growth rate of 20%.
Amedisys has a long-term expected earnings growth rate of 17.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look.
See the pot trades we're targeting>>